Pradaxa Lawsuits Settle for Millions

The litigation surrounding the well-known drug Pradaxa finally reached a resolution last month when Boehringer Ingelheim Pharmaceuticals, Inc., the drug’s manufacturer, settled the pending lawsuits for 650 million dollars. Pradaxa, otherwise known as dabigatran, is an anticoagulant that has been on the market since October of 2010. The drug is intended to be used for the prevention of strokes and blood clots in patients with atrial fibrillation and works by thinning the patient’s blood. It was introduced in 2010 as a competitor to warfarin, a different anticoagulant that is known to cause several undesirable and debilitating side effects. Furthermore, in addition to its numerous side effects, warfarin also typically requires frequent doctor visits and considerable lifestyle and diet changes in those who take it. Pradaxa, on the other hand, was developed to be a safer and more convenient alternative.

By the middle of 2010, nearly four million patients were being prescribed Pradaxa in the United States alone. That same year, Boehringer Ingelheim Pharmaceuticals, Inc. made $1.5 billion in sales of Pradaxa. Unfortunately, not long after its FDA approval, Pradaxa began to be blamed for the deaths of hundreds of patients taking the medication. The primary complaint was hemorrhaging and uncontrollable bleeding. To date, over four thousand lawsuits have been filed in the U.S. against the pharmaceutical company for complications experienced while taking the medication.

Following the results of a number of investigations-including one by the FDA-Pradaxa was not definitely found to be responsible for these deaths and/or medical complications. Unfortunately, a conclusive result is not likely, because bleeding complications are a risk involved with taking any of the anticoagulants on the market. Nevertheless, on May 28, 2014 Boehringer Ingelheim Pharmaceuticals, Inc. decided to settle the thousands of pending lawsuits by agreeing to a $650 million civil settlement. The company’s Head of the Legal Department and General Counsel stated that they stand behind Pradaxa and while they feel the plaintiffs’ claims lacked merit, they decided to settle the cases in lieu of enduring protracted litigation.

If you or a loved one has been injured by the drug Pradaxa, contact The Higgins Firm today. Our experienced litigation attorneys are ready to discuss your legal options with you during a free initial consultation. Don’t delay; you could be entitled to significant financial compensation.

Author Bio

Jim Higgins, founder of the Higgins Firm, is a seasoned personal injury attorney with deep roots in Nashville, Tennessee. A 4th generation Nashvillian, Jim carries on the legal legacy of his father, a judge for over 30 years. After graduating from the University of Memphis School of Law, Jim’s career began on the other side of the courtroom, defending insurance companies and learning their tactics for minimizing settlements. However, he soon realized his true calling was fighting for the rights of the injured, and for the past several years, he has exclusively represented plaintiffs in personal injury cases.

Since then, his dedication and skill have earned him membership in the prestigious Million Dollar Advocates Forum, an organization limited to attorneys who have secured million and multi-million dollar verdicts and settlements for their clients. Licensed to practice in Tennessee, Kentucky, and Georgia, Jim focuses on personal injury, product liability, medical malpractice, and workers’ compensation cases. His exceptional work has been recognized by his peers, earning him a spot on the Super Lawyers list from 2021 to 2024, a distinction awarded to only a select group of accomplished attorneys in each state.

Google | Linked In | Avvo | State Bar Association